For innovative companies operating in London, the landscape of Research & Development (R&D) tax relief has seen a significant transformation. The UK government introduced a new merged R&D scheme, which applies to accounting periods starting on or after 1 April 2024. This change replaces the former SME and RDEC schemes, creating a single, unified system for most businesses. This guide offers a focused and comprehensive look at this important tax change. It explains who it affects, details the new expenditure credit rate, outlines updates to eligible costs, and provides essential steps for making a successful claim. Prepare your company to secure its R&D tax benefits under this new system.
Understanding the Merged R&D Tax Relief Scheme
The UK’s R&D tax relief system is a key government incentive to encourage innovation. The introduction of the new merged R&D scheme marks a significant step in simplifying and refining this support. It is important to grasp its core nature and the overarching objectives behind its creation.
What is the Merged R&D Scheme?
The merged R&D scheme is a single, unified tax credit system that replaces the previous R&D Expenditure Credit (RDEC) and SME schemes. For most companies, the distinction between these two former schemes no longer applies. This new scheme operates as an “above-the-line” credit. This means that the R&D tax credit is treated as taxable income within your company’s profit and loss account, rather than a reduction in your taxable profit or a direct offset against your tax bill. This approach aims to make the value of the R&D incentive more visible in a company’s accounts.
Key Objectives of the New Scheme
HMRC introduced the merged R&D scheme with several important goals:
Simplify the R&D tax relief system: By combining the two previous schemes into one, the government aims to make the process less complex for companies to understand and claim.
Make it more accessible: A simpler system should encourage more eligible companies, particularly those new to R&D claims, to participate.
Encourage R&D activity within the UK: The scheme continues to support and incentivise companies to conduct their research and development work within the United Kingdom.
Improve compliance: Changes aim to reduce opportunities for abuse and ensure that only genuine R&D activities receive tax relief.
Who is Affected? Applicability and Exceptions
The new merged R&D scheme applies broadly to companies engaged in qualifying research and development activities. It is important to understand when this new scheme comes into effect for your company and to recognise the specific exception for R&D-intensive SMEs.
Accounting Periods Starting On or After 1 April 2024
The merged R&D scheme applies to accounting periods beginning on or after 1 April 2024. This effective date is crucial for determining when your company transitions to the new rules.
Example 1: Company with a 31 March year-end: Your accounting period from 1 April 2024 to 31 March 2025 will be the first period under the new merged scheme.
Example 2: Company with a 31 December year-end: Your accounting period from 1 January 2025 to 31 December 2025 will be your first period under the new merged scheme, as your period starting 1 January 2024 still falls under the old rules. Companies must apply the rules that are in force for their specific accounting period.
All Companies in Scope (Replacing SME and RDEC Schemes)
For most companies undertaking R&D, this single, unified scheme now applies. This means the previous distinction between the SME scheme (for small and medium-sized enterprises) and the RDEC scheme (for large companies) is largely gone. Companies no longer need to determine which of the two former schemes they fall under based on their size or turnover. This change aims to simplify the rules for many businesses, providing a more consistent approach to R&D tax relief across the corporate landscape.
Exception: Enhanced R&D Intensive Support (ERIS) for Loss-Making SMEs
While the merged scheme applies to most companies, there is an important exception for certain R&D-intensive SMEs. This is known as the Enhanced R&D Intensive Support (ERIS) scheme, a specific carve-out designed to provide more generous support to loss-making small and medium-sized enterprises that have significant R&D expenditure.
Eligibility: To qualify for ERIS, an SME must be loss-making and have R&D intensity of 30% or more for accounting periods beginning on or after 1 April 2024. R&D intensity is calculated by comparing qualifying R&D expenditure to the company’s total expenditure.
Benefit: Qualifying SMEs can claim a more generous payable credit under ERIS. The payable credit rate is 14.5% of the surrenderable loss that is attributable to R&D. This is a higher cash credit rate than that available under the main merged scheme for loss-making companies and is designed to provide greater cash flow support to highly innovative, loss-making businesses. The rules for ERIS are similar to the old SME scheme’s payable credit rules.
Key Changes Under the Merged R&D Scheme
The new merged R&D scheme introduces several important changes that directly impact how companies calculate and claim R&D tax relief. These updates affect the credit rate, what costs are eligible, and how subcontracted R&D is treated.
The Expenditure Credit Rate (20%) and Effective Benefit
The headline rate of the expenditure credit under the new merged scheme is 20%. This is the rate applied to your company’s qualifying R&D expenditure.
How the 20% Credit is Applied (Above-the-Line)
The 20% credit is an “above-the-line” credit. This means it is treated as taxable income within your company’s profit and loss account. It reduces the company’s taxable profits or increases its loss before Corporation Tax is calculated. This approach aims to make the R&D incentive more visible in a company’s financial statements.
Net Benefit based on Corporation Tax Rate (e.g., 15% or 16.2%)
The actual net benefit your company receives from the 20% expenditure credit depends on its Corporation Tax rate. The credit itself is taxable.
For profitable companies: If your company pays Corporation Tax at the main rate of 25%, the effective net benefit is 15% of your qualifying R&D expenditure. This is calculated as 20% (the credit) minus 25% Corporation Tax on that 20% credit (20% * 0.25 = 5%), so 20% – 5% = 15%.
For loss-making companies: If your company is loss-making and surrenders the credit for a cash payment, the payable rate is effectively 16.2%. This is calculated as 20% (the credit) minus a notional 19% Corporation Tax on that credit (20% * 0.19 = 3.8%), so 20% – 3.8% = 16.2%. The net benefit is paid out to the company as a reduction in its tax bill or a cash payment.
Changes to Eligible Expenditure
The definition of qualifying R&D expenditure has been updated under the merged scheme, impacting what costs companies can claim.
Inclusion of Data Licenses and Cloud Computing Costs
For accounting periods starting on or after 1 April 2023, costs for data licenses and cloud computing services directly used in R&D activities are now explicitly included as eligible expenditure. This is a welcome change for many modern, innovative companies, particularly in London’s tech sector, as these costs are increasingly central to R&D projects. This includes costs for data sets, cloud storage, and processing power directly consumed in R&D.
Restriction on Overseas R&D Costs (with Exceptions)
A significant new restriction under the merged scheme is that costs for Externally Provided Workers (EPWs) and subcontractors are generally only eligible if the R&D activity takes place in the UK. This aims to focus R&D tax relief on innovation conducted within the UK. However, there are limited exceptions where overseas R&D costs may still qualify:
Geographical, Environmental, or Social Conditions: Where the conditions necessary for the R&D are not present in the UK, and it would be wholly unreasonable to replicate them in the UK (e.g., R&D requiring specific geological features, extreme climates, or unique social demographics not found in the UK).
Legal or Regulatory Requirements: Where legal or regulatory requirements mandate that the R&D activity must be carried out overseas. These exceptions are narrowly defined and require clear justification.
New Rules for Subcontracted R&D and Externally Provided Workers (EPWs)
The merged scheme introduces a revised approach to subcontracted R&D and Externally Provided Workers (EPWs), clarifying who can claim relief.
“Initiator” Principle: The general rule is that the right to claim R&D tax relief for subcontracted R&D generally rests with the company that initiated the R&D and bears the financial risk of the R&D project, rather than the subcontractor performing the work. This means the company commissioning the R&D (the customer) will typically claim for the costs of the subcontracted work.
65% Cap for Unconnected Parties: For subcontracted R&D where the subcontractor is an unconnected party, the company claiming relief can include 65% of the payment made to the subcontractor as qualifying expenditure. For connected parties, 100% of the payment can be claimed, subject to certain conditions.
EPWs: Costs for EPWs are also generally claimable by the company that uses them for R&D, subject to the overseas restriction mentioned above.
Essential Steps for Claiming Under the Merged Scheme
Making a successful R&D tax relief claim under the new merged scheme requires a structured approach. Companies need to follow specific steps, from identifying qualifying projects to capturing eligible expenditure and adhering to new notification requirements.
Identifying Qualifying R&D Projects
The first and most important step is to accurately assess if your company’s activities meet HMRC’s specific definition of R&D for tax purposes. This definition is narrower than a general business understanding of innovation.
Definition of R&D for Tax Purposes (Advance in Science or Technology)
R&D for tax purposes involves seeking an advance in overall knowledge or capability in a field of science or technology. It is not simply about improving your company’s own products or processes, but about achieving a genuine scientific or technological advancement that a competent professional could not readily achieve. The project must aim to create new knowledge or overcome a scientific or technological uncertainty.
Identifying Scientific or Technological Uncertainty
A key element of qualifying R&D is that it aims to resolve scientific or technological uncertainty. This means that at the outset of the project, a competent professional working in that field could not readily know whether a goal could be achieved, or how to achieve it in practice. This uncertainty must be genuine and relate to science or technology, not just commercial or market uncertainty. The R&D activities are the systematic investigation undertaken to resolve this uncertainty.
Capturing Qualifying Expenditure
Once you identify qualifying R&D projects, you must meticulously identify and track all eligible costs associated with those activities.
Staff Costs (PAYE, NICs, Pension Contributions)
Staff costs for employees directly engaged in R&D activities are a significant component of most claims. This includes:
- PAYE Earnings: The gross earnings (salary, wages, bonuses) of employees directly involved in R&D.
- Class 1 NICs: The employer’s Class 1 National Insurance Contributions paid on those eligible earnings.
- Pension Contributions: Employer pension contributions made for employees directly engaged in R&D. You can also claim a proportion of staff costs for employees who indirectly support R&D (e.g., administrative staff managing R&D projects), but these must be clearly linked.
Consumables and Software
Costs of materials, utilities, and software directly used in the R&D process are eligible:
Consumables: Materials, utilities (light, heat, power, water), and other items consumed or transformed in the R&D process (e.g., raw materials used to build a prototype).
Software: Costs of software licenses and cloud computing services directly used for R&D activities (for accounting periods starting on or after 1 April 2023). This includes software used for design, modelling, testing, and data analysis related to the R&D.
New Pre-Notification Requirements for First-Time Claimants
A crucial new compliance requirement under the merged scheme affects companies making their first R&D claim or those who have not claimed in the last three years.
Notification Requirement: Such companies must notify HMRC of their intention to claim R&D tax relief within 6 months of the end of the accounting period to which the claim relates.
Consequence of Failure: Failure to pre-notify HMRC within this timeframe will invalidate the R&D claim for that accounting period. This new requirement aims to give HMRC earlier visibility of R&D claims. Companies that have claimed R&D tax relief in any of the previous three accounting periods are generally exempt from this pre-notification requirement.
Benefits for London’s Innovative Companies
The new merged R&D scheme, despite its changes, presents significant advantages and opportunities for London-based businesses committed to innovation. These benefits can translate into substantial tax savings or cash injections, supporting further R&D investment and growth.
Simplified Scheme for Most Companies
The introduction of a single, merged scheme aims to simplify the claims process for many companies. By replacing the previous distinction between the SME and RDEC schemes, businesses no longer need to:
Determine their size classification (SME or large company) for R&D purposes.
Navigate the different rules and rates of two separate schemes. This simplification reduces administrative complexity and the potential for errors, making R&D tax relief more accessible and straightforward for a broader range of businesses.
More Generous PAYE/NIC Cap
The PAYE/NIC cap on payable credits (for loss-making companies surrendering their R&D credit for cash) has become more generous under the merged scheme.
The maximum payable credit is now generally limited to £20,000 plus 300% of the company’s total PAYE and National Insurance Contributions (NIC) liability for the period. This increased buffer benefits loss-making companies, particularly those with high R&D expenditure but relatively low PAYE/NIC liabilities, allowing them to receive a larger cash credit from HMRC. This provides crucial cash flow support for innovative businesses in their early, loss-making stages.
Removal of Restrictions for Subsidised Expenditure
Under the previous SME scheme, complex rules applied to R&D expenditure that had received grants or subsidies, often restricting the amount of R&D tax relief that could be claimed. The merged scheme generally removes these complex rules.
This means that companies with R&D projects that are also supported by grants or subsidies can now claim the full R&D expenditure credit on their qualifying costs, without needing to make complicated adjustments for the subsidised element. This simplification streamlines calculations and ensures companies are not penalised for also seeking grant funding for their innovative projects.
Ensuring Visibility with AZL
For London’s innovative companies, adapting to the new merged R&D scheme requires clarity and confidence. At AZL, we enhance your understanding and control over this evolving R&D landscape and your claim process. Our expert accountants transform the complexities of R&D tax relief into a transparent and manageable opportunity for your business.
How AZL Helps Your Company Adapt to the Merged R&D Scheme
AZL provides specific services to help your company seamlessly adapt to the new merged R&D scheme:
- Legislation Interpretation: Our experts interpret the new legislation, explaining how the changes impact your specific R&D projects and overall tax position in clear, accessible language.
- Eligibility Assessment: We conduct thorough assessments of your R&D activities and expenditure against the new rules, accurately determining your eligibility for the merged scheme or the ERIS exception.
- Impact Analysis: We advise on how the changes affect your potential R&D tax benefits, helping you understand the financial implications for your business.
Streamlining Your R&D Claim Process with AZL
AZL plays a crucial role in efficiently preparing and submitting robust R&D claims under the new rules, ensuring accuracy and maximizing your potential benefits.
Data Capture Guidance: We guide you on establishing systems for capturing all qualifying R&D expenditure, including staff costs, consumables, and software licenses.
Technical and Financial Report Preparation: We assist in preparing both the technical narrative (explaining the R&D projects and uncertainties) and the financial calculations required for your claim.
Pre-Notification Management: For first-time claimants, we manage the new pre-notification process to HMRC, ensuring this critical requirement is met on time.
HMRC Submission: We prepare and submit your R&D claim to HMRC, ensuring all necessary forms and supporting documentation are accurately filed.
Inclusive Guidance for Diverse London Companies
The new merged R&D scheme affects a wide range of innovative companies in London, from burgeoning start-ups to established multinational groups. AZL provides inclusive guidance, ensuring our advice is tailored to the specific needs and structures of diverse businesses, fostering innovation across the capital.
Support for Start-ups and Growing SMEs
The new R&D landscape offers specific support for smaller businesses:
- ERIS for Loss-Making Start-ups: We provide insights into how the Enhanced R&D Intensive Support (ERIS) scheme can be crucial for loss-making R&D-intensive start-ups, offering a more generous payable credit to support their cash flow.
- Simplified Merged Scheme: For growing SMEs that are profitable or less R&D-intensive, the simplified merged scheme reduces the complexity of claiming, making the process more accessible.
- Cash Flow Support: We highlight how the payable credit (under ERIS or the main scheme’s surrenderable credit) provides vital cash flow support for early-stage and growing businesses.
Advice for Large Companies and Multinational Groups
The merged scheme streamlines claims for larger companies, which previously claimed under RDEC, and impacts multinational R&D operations:
- Consistent Application: The single scheme provides a consistent framework for large companies, simplifying their R&D tax calculations compared to the former RDEC rules.
- Overseas R&D Impact: We advise multinational groups on the new restrictions on overseas R&D costs and the limited exceptions, helping them assess the impact on their global R&D operations.
- Group Claims: Guidance on how the merged scheme applies to group companies and how to structure claims for optimal benefit across a multinational group.
Businesses with Subcontracted R&D Activities
The new “right to claim” rules for subcontracted R&D have a significant impact on both companies commissioning R&D and those undertaking R&D as subcontractors.
Commissioning Companies: We clarify that the company initiating the R&D and bearing the risk is generally the one that claims for the subcontracted R&D costs.
Subcontractors: We advise subcontractors on when they can (or cannot) claim R&D tax relief for work performed for clients, ensuring they do not duplicate claims or miss out on eligible relief.
Contract Review: We can assist in reviewing contracts for R&D services to ensure they clearly define who is entitled to claim the R&D tax relief.
How AZL’s Experts Can Assist You
At AZL, our expert accountants are your indispensable partners in navigating the complexities of the new merged R&D scheme for your London company. With over a decade of experience in accounting, finances, and tax compliance, we deliver specialized support that ensures precision, unwavering compliance, and ultimately, maximizes your R&D tax benefits. We are committed to providing clarity, instilling confidence, and protecting your financial interests as you drive innovation.
H3: R&D Eligibility Assessment and Project Scoping
AZL provides tailored services to help you accurately identify and scope your qualifying R&D activities:
- Thorough Eligibility Review: Our experts conduct a detailed review of your company’s activities against HMRC’s definition of R&D, identifying projects that qualify for tax relief under the new merged scheme or ERIS.
- Technical and Financial Scoping: We work with your technical teams to understand the scientific or technological uncertainties your projects aim to resolve, and then translate these into a robust R&D claim.
- Cost Identification: We help you identify all eligible expenditure, including staff costs, consumables, software licenses, and qualifying subcontracted R&D, ensuring no legitimate costs are missed.
- AZL ensures your R&D claim is built on a strong, compliant foundation.
Comprehensive Claim Preparation and HMRC Submission
AZL provides end-to-end support for preparing and submitting your R&D claim to HMRC, ensuring accuracy and adherence to all new requirements:
- Documentation Gathering: We assist with gathering all necessary financial and technical documentation to support your claim, including project records, timesheets, and invoices.
- Claim Calculation: Our experts meticulously calculate your qualifying expenditure and the resulting expenditure credit or payable credit, ensuring precision and maximizing your potential benefit.
- Report Preparation: We prepare the technical narrative and financial reports that accompany your R&D claim, clearly articulating how your projects meet HMRC’s criteria.
- New Pre-Notification Adherence: For first-time claimants or those who haven’t claimed in three years, we manage the new pre-notification process to HMRC, ensuring this critical requirement is met on time.
- HMRC Submission: We submit your R&D claim to HMRC, often as part of your Corporation Tax return (CT600), and handle any subsequent queries from HMRC.